Trilaciclib for bone marrow protection during chemotherapy
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer and plan to receive chemotherapy.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- Your blood counts, liver and kidney function, and heart tests are within normal ranges.
- You do not have certain lung diseases, blood cancers, or sickle cell disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a drug called trilaciclib to see if it can protect your blood cell counts during treatment for head and neck cancer that has come back or spread. You must not have had chemotherapy before for this stage of cancer.
This study tests a drug called Trilaciclib to see if it can prevent low blood cell counts caused by a type of chemotherapy called topoisomerase I inhibitor ADCs. If you are getting this kind of chemo, you may be able to join.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.